Patents by Inventor Leonid Beigelman

Leonid Beigelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220380770
    Abstract: The present invention is in the field of pharmaceutical compounds and preparations and method of their use in the treatment of disease. Described are short interfering nucleic acid (siNA) molecules comprising modified nucleotides, compositions containing the same, and uses thereof for treating or preventing coronavirus infections. In particular, the present invention is in the field of siNA molecules effective against a broad spectrum of coronaviruses, and especially the ?-coronaviruses, including SARS-CoV-2, the causative agent of COVID-19.
    Type: Application
    Filed: April 9, 2021
    Publication date: December 1, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: Leonid BEIGELMAN, Antitsa STOYCHEVA, Aneerban BHATTACHARYA, David Bernard SMITH, Rajendra K. PANDEY, Saul Martinez MONTERO, Vivek Kumar RAJWANSHI, Jin HONG
  • Publication number: 20220363640
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: March 22, 2021
    Publication date: November 17, 2022
    Applicant: Janssen BioPharma, Inc.
    Inventors: Guangyi WANG, Leonid BEIGELMAN, Anh TRUONG, Carmela NAPOLITANO, Daniele ANDREOTTI, Haiying HE, Karin Ann STEIN
  • Publication number: 20220364096
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: March 5, 2021
    Publication date: November 17, 2022
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Patent number: 11492367
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R, R1B, R1C, R2B, R2C, B1, W, X, Y, Z are defined herein.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 8, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Stuart Emanuel, Mark Richter, Peter J. Connolly, James Patrick Edwards, Guangyi Wang, Santhosh Kumar Thatikonda, Leonid Beigelman, Minghong Zhong, Gilles Bignan, Wim Schepens, Marcel Viellevoye, Johannes Wilhelmus John Fitzgerald Thuring
  • Patent number: 11485753
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: November 1, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith
  • Patent number: 11472830
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: October 18, 2022
    Assignee: Janssen Biotech, Inc.
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Patent number: 11472826
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HBV and/or HDV and/or HIV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Leonid Beigelman, Guangyi Wang, Minghong Zhong
  • Patent number: 11466274
    Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: October 11, 2022
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Rajendra K. Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Jin Hong
  • Patent number: 11453881
    Abstract: Oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: September 27, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Andreas Ebneth, Constantin Van Outryve D'Ydewalle, Sergei Gryaznov, Saúl Martinez Montero, Leonid Beigelman, Vivek Kumar Rajwanshi
  • Publication number: 20220275366
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin NA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: October 8, 2021
    Publication date: September 1, 2022
    Inventors: James McSwiggen, Leonid Beigelman
  • Publication number: 20220177888
    Abstract: Disclosed herein are short interfering nucleic acid (siNA) molecules comprising modified nucleotides and uses thereof. The siNA molecules may be double stranded and comprise modified nucleotides selected from 2?-O-methyl nucleotides and 2?-fluoro nucleotides. Further disclosed herein are siNA molecules comprising (a) a phosphorylation blocker, conjugated moiety, or 5?-stabilized end cap; and (b) a short interfering nucleic acid (siNA).
    Type: Application
    Filed: February 15, 2022
    Publication date: June 9, 2022
    Applicant: Aligos Therapeutics, Inc.
    Inventors: Leonid Beigelman, Vivek Kumar Rajwanshi, Markus Hossbach, Rajendra K. Pandey, Jin Hong, Laxman Eltepu, Saul Martinez Montero, N. Tilani S. De Costa
  • Publication number: 20220160748
    Abstract: Disclosed herein is an oligonucleotide conjugate or complex thereof, comprising a modified oligonucleotide having sequence independent antiviral activity against hepatitis B, a liver targeting agent, and a linker connecting the liver targeting agent to a 3? end and/or a 5? end of the modified oligonucleotide or complex thereof. The oligonucleotide conjugate may be incorporated into a pharmaceutical composition for treating a liver disease or disorder such as hepatitis B.
    Type: Application
    Filed: November 18, 2021
    Publication date: May 26, 2022
    Inventors: Leonid Beigelman, Megan Elizabeth Fitzgerald, Rajendra Pandey, Jin Hong, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt
  • Publication number: 20220143032
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Publication number: 20220144811
    Abstract: Disclosed herein are compounds of Formula I: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Publication number: 20220143031
    Abstract: Disclosed herein are compounds of Formula I?: or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising such compounds, and methods of treating disease by administering or contacting a subject with one or more of the above compounds.
    Type: Application
    Filed: November 5, 2021
    Publication date: May 12, 2022
    Applicant: ALIGOS THERAPEUTICS, INC.
    Inventors: David Craig McGowan, Pierre Jean-Marie Bernard Raboisson, Koen Vandyck, Jerome Deval, Leonid Beigelman
  • Publication number: 20220125825
    Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.
    Type: Application
    Filed: October 26, 2021
    Publication date: April 28, 2022
    Inventors: Leonid Beigelman, Rajendra Pandey, Vivek Kumar Rajwanshi, David Bernard Smith, Lawrence M. Blatt, Jin Hong
  • Publication number: 20220112194
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 30, 2021
    Publication date: April 14, 2022
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing, Francois Gonzalvez
  • Publication number: 20220071957
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 16, 2021
    Publication date: March 10, 2022
    Inventors: Sandrine Vendeville, David Bernard Smith, Leonid Beigelman, Vladimir Serebryany, Raymond F. Schinazi, Franck Amblard, Leda Bassit
  • Publication number: 20220056441
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: November 25, 2020
    Publication date: February 24, 2022
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • Publication number: 20220056451
    Abstract: Oligonucleotides that target hepatitis B virus (HBV) viral sequences, such as rcDNA, cccDNA, and HBV transcripts, are described herein. In addition, compositions and kits comprising such oligonucleotides are further described. Further disclosed herein are uses of such oligonucleotides and compositions to reduce rcDNA to cccDNA conversion, reduce cccDNA levels, and/or treat an HBV infection.
    Type: Application
    Filed: July 26, 2021
    Publication date: February 24, 2022
    Inventors: Jin Hong, Leonid Beigelman, Aneerban Bhattacharya, N. Tilani S. De Costa